Published by Josh White on 17th November 2023
(Sharecast News) - AstraZeneca's 'Truqap', or capivasertib, in combination with 'Faslodex', or fulvestrant, has secured approval from the US Food and Drug Administration (FDA) for specific breast cancer treatments, the company announced on Friday.
URL: http://www.digitallook.com/dl/news/story/33914858/...